# SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies

> **NCT07738757** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies

## Interventions

- **DRUG:** Sacituzumab Tirumotecan (Sac-TMT)
- **DRUG:** Tagitanlimab

## Key facts

- **NCT ID:** NCT07738757
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738757, "SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological Malignancies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07738757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*